GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Neuroscience and Physiology / Inst för neurovetenskap och fysiologi >
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi >

Quantitative Clinical Pharmacological Studies on Efavirenz and Atazanavir in the Treatment of HIV-1 Infection


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/29725

Files in This Item:

File Description SizeFormat
gupea_2077_29725_1.pdfThesis frame1603KbAdobe PDF
View/Open
gupea_2077_29725_3.pdfAbstract161KbAdobe PDF
View/Open
Title: Quantitative Clinical Pharmacological Studies on Efavirenz and Atazanavir in the Treatment of HIV-1 Infection
Authors: Rekić, Dinko
E-mail: dinko.rekic@gu.se
dinko.rekic@gmail.com
Issue Date: 22-Nov-2012
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Neuroscience and Physiology. Department of Pharmacology
Parts of work: Rekić D, Röshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype. British Journal of Clinical Pharmacology. 2011; 71 (4):536–43.
VIEW ARTICLE


Mukonzo JK, Nanzigu S, Rekić D, Waako Paul, Röshammar D, Ashton M, Ogwal-Okeng J, Gustafsson LL, Aklillu E. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clinical Pharmacokinetics. 2011; 50 (8):531–40.
VIEW ARTICLE


Rekić D, Clewe O, Röshammar D, Flamholc L, Sönnerborg A, Ormaasen V, Gisslén M, Äbelö A, Ashton M. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. The AAPS journal. 2011 Sep 13; 13 (4):598–605.
VIEW ARTICLE


Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Äbelö A. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients. Submitted

Rekić D, Röshammar D, Simonsson USH. Model based design and analysis of phase II HIV-1 trials. Submitted
Date of Defence: 2012-12-14
Disputation: Fredagen den 14 december 2012, kl. 13.00, Hörsal Björn Folkow, Medicinaregatan 11, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: HIV
Pharmacokinetics
Pharmacodynamics
Pharmacometrics
AIDS
Abstract: There are 34 million people infected with the HIV-1 virus in the world today. Due to increased access to antiretroviral therapy, AIDS related death has dropped by 30% since 2005. Optimizing the pharmacotherapy of the HIV-1 infection is of great importance to reduce adverse effects, reduce viral resistance development and increase the patients’ survival as well as quality of life. This thesis presents pharmacometric applications to optimize pharmacotherapy of the HIV-1 infection as well as to exp... more
ISBN: 978-91-628-8590-8
URI: http://hdl.handle.net/2077/29725
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi

This item has been viewed 132 times.

 

 

© Göteborgs universitet 2011